Kala Bio Inc (NAS:KALA)
$ 6.865 0.0486 (0.71%) Market Cap: 19.34 Mil Enterprise Value: 4.63 Mil PE Ratio: 0 PB Ratio: 2.51 GF Score: 51/100

Q4 2021 Kala Pharmaceuticals Inc Earnings Call Transcript

Mar 29, 2022 / 12:00PM GMT
Release Date Price: $75 (-14.29%)
Operator

Good morning, and welcome to Kala Pharmaceuticals conference call to review its fourth quarter and full year 2021 financial results. (Operator Instructions) As a reminder, this call is being recorded.

I would like to turn the call over to Jill Steier, Executive Director, Investor Relations and Corporate Communications for Kala Pharmaceuticals. Please proceed.

Jill S. Steier
Kala Pharmaceuticals, Inc. - Executive Director of IR & Corporate Communications

Thank you, operator, and thank you all for participating in today's call. Joining me from the company are Mark Iwicki, Chairman and Chief Executive Officer; Todd Bazemore, President and Chief Operating Officer; Kim Brazzell, Head of R&D and Chief Medical Officer; Mary Reumuth, Chief Financial Officer; and Darius Kharabi, our Chief Business Officer, will also be joining us for the Q&A portion of today's call.

Today's call is being webcast live. The webcast link can be found in the Investors section of our website at www

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot